Skip to content
TrialScanner

NCT02557321

PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma

Phase 1/Phase 2Unknown statusPVCTLead

Registry record

Lead sponsor
Provectus Biopharmaceuticals, Inc.
Conditions
Melanoma
Primary completion
May 2023Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT02557321 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT02557321: PV-10 in Combination With... | TrialScanner